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Localization and interactions of vasoactive peptide receptors in
renomedullary interstitial cells of the kidney. Vasoactive peptides
regulate renal medullary microcirculation and tubular function,
but the localization of their receptors and mechanisms of actions
are currently unknown. Using electron microscopic autoradiogra-
phy, we have mapped the receptors for angiotensin II (Ang II
[AT1 and AT2]), endothelin (ETA and ETB), and bradykinin (B2)
in the rat renal medulla. Although these peptide receptors show
distinct vascular and tubular distributions, they overlap strikingly
in renomedullary interstitial cells (RMICs) of the inner stripe and
the papilla. Using reverse transcription-polymerase chain reaction
(RT-PCR) and Southern analysis, mRNAs for AT1A, ETA, and B2
receptors were detected in cultured adult RMICs. Ang II in-
creases intracellular inositol 1,4,5-triphosphate (IP3) and [Ca
21]i
and stimulates [3H]thymidine incorporation and extracellular
matrix (ECM) synthesis via AT1A receptors. Endothelin and
bradykinin also stimulate cell proliferation and ECM synthesis in
RMICs through ETA and B2 receptors, respectively, but the
actions of endothelin are modulated by concurrent nitric oxide
production. By contrast, AT2 receptor mRNA was detected only
in embryonic RMICs, in which Ang II inhibits cell proliferation
through this receptor. These results suggest that multiple vasoac-
tive peptides may interact with RMICs to exert endocrine and/or
paracrine influences on renal medullary microcirculation and
tubular function.
The renal medulla plays an important role in maintaining
body fluid and electrolyte balance and blood pressure
homeostasis through actions of various humoral and para-
crine/autocrine factors on renal medullary hemodynamics,
tubular reabsorption, and urine concentration [1]. Angio-
tensin II (Ang II), endothelin (ET), and bradykinin (BK)
are vasoactive peptides that have been implicated in the
regulation of renal medullary function [1, 2]. In the renal
medulla, physiological studies have shown that these vaso-
active peptides either act alone or interact with each other
to influence medullary/papillary blood flow and urinary
water and sodium excretion [1–3]. However, the precise
sites and cellular mechanisms of actions of the vasoactive
peptide receptors in the renal medulla are not fully under-
stood. The aim of this article is to review current under-
standing of the cellular localization of the receptors for
Ang II (AT1), ET (ETA and ETB), and BK (B2) and their
actions in type I renomedullary interstitial cells (RMICs)
and other cellular structures in the rat renal medulla.
CELLULAR LOCALIZATION AND ACTIONS OF AT1
RECEPTORS IN RMICS
Evidence that Ang II may regulate renal medullary and
papillary microcirculation and countercurrent exchange
mechanisms came from early physiological studies showing
medullary blood flow and/or papillary blood flow to be
reduced markedly by sodium restriction and/or depletion or
by infusion of exogenous Ang II [1, 3]. Conversely, angio-
tensin converting enzyme (ACE) inhibitors, or Ang II
receptor antagonists, exerts opposite effects [1–3]. How-
ever, little is known about either the mechanisms respon-
sible for the regulation of these physiological processes at
the receptor level or the precise cellular location of Ang II
receptors in the renal medulla.
We therefore evaluated the cellular localization of AT1
receptors in the inner stripe of the outer medulla using
high-resolution light and electron microscopic autoradiog-
raphy [4]. Fresh tissue slices were dissected from the inner
stripe of the outer medulla instead of using frozen tissue
sections [4]. This technique permits localization of AT1
receptor at the cellular and subcellular levels while preserv-
ing cellular morphology. Light microscopy confirmed that a
high density of AT1 receptor binding occurs in the inner
stripe, where silver grains are found outlining, but distinct
from, renal tubules and the vasa recta bundles (Fig. 1A).
Cellular identification was confirmed by electron micro-
scopic autoradiography, where the distribution of silver
grains is seen almost exclusively on RMICs situated be-
tween the vasa recta and tubules (Fig. 2A). No appreciable
binding is observed over the cells of the descending thin
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limb and ascending thick limb of the loop of Henle, the
medullary collecting duct, or the vasa recta [4]. At high
magnification, these AT1 receptor-bearing interstitial cells
show long cytoplasmic projections, lipid droplets, cisternae
of rough endoplasmic reticulum, free ribosomes, lyso-
somes, and vacuoles in the cytoplasm, along with small
bundles of microfilaments [4]. These histological character-
istics resemble those of type I interstitial cells [5].
AT1 receptors on RMICs of the inner stripe of the outer
medulla appear to be regulated physiologically in a similar
manner to those in glomerular mesangial cells [6]. Parallel
changes in AT1 receptor binding occur in both the glomer-
ulus and the inner stripe during altered dietary sodium
intake [6]. Although these changes might result directly
from altered AT1 receptor mRNA expression [7], in vivo
occupancy of these receptors by both circulating and in-
trarenally formed Ang II might also contribute to this
receptor regulation [6]. This proposition is supported by a
striking difference in cortical and medullary AT1 receptor
binding in rats following in vitro and in vivo labeling [6, 8].
Although AT1 receptors in glomeruli and proximal tubules
are labeled similarly by both techniques, the binding sites in
the inner stripe of the outer medulla, as visualized by in
vitro autoradiography, are not readily labeled in vivo by the
vascularly delivered radioligands, 125I-Ang II or its antag-
onist analogue 125I-[Sar1,Ile8]Ang II [8]. This lack of AT1
receptor binding in the inner stripe following systemic
delivery of the radioligands appears not to be due to Ang
II-induced renal vasoconstriction, because prior renal va-
sodilatation induced by sodium nitroprusside fails to in-
crease AT1 receptor labeling in RMICs of the inner stripe.
In contrast, chronic salt loading or inhibition of ACE with
perindopril both significantly increases AT1 receptor bind-
ing to the type 1 RMICs in vivo [8]. These findings may be
explained by the observation that intrarenal Ang II levels
are much higher than circulating Ang II under physiologi-
cal conditions [9]. A recent study using in vivo microdialy-
sis, in which nanomolar levels of Ang II were reported in
the renal interstitial fluid, lends further support to our
interpretation [10]. Although the physiological significance
of this in vivo occupancy of AT1 receptors in RMICs is
unclear, endogenous interstitial Ang II may interact with
RMICs to modulate indirectly renal cortical and medullary
hemodynamics and tubular function under certain physio-
logical and pathophysiological states.
High-affinity Ang II receptor binding sites have been
reported previously in cultured rabbit RMICs in which Ang
II stimulates prostaglandin (PG) synthesis [11]. We re-
cently showed that cultured rat RMICs also express AT1
receptors [12, 13]. Using reverse transcription-polymerase
chain reaction (RT-PCR) and Southern blot analysis, we
subsequently confirmed that the AT1 receptors on cultured
RMICs are exclusively the AT1A subtype: no AT1B receptor
mRNA was detected [13]. In contrast, the whole rat kidney
expresses both AT1A and AT1B receptors, with the former
Fig. 1. In vitro autoradiographic mapping of angiotensin I receptor
(AT1) (A), endothelin (ET)B (B) and bradykinin B2 receptors (C) in the
rat kidney. (A) AT1 receptor binding is determined by
125I-[Sar1,Ile8] Ang
II binding in the presence of the AT2 receptor antagonist, PD 123319 (10
mM). (B) ETB receptor binding is determined by
125I-ET-1 binding in the
presence of the ETA receptor antagonist, BO123 (1 mM). (C) B2 receptor
binding is determined by the binding of specific B2 receptor radioligand,
125I-HPP-HOE140. Red indicates highest binding density, blue the back-
ground level. Abbreviations are: G, glomerulus; PT, proximal tubule; IS,
inner stripe of the outer medulla; IM, inner medulla.
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predominating [12]. In cultured RMICs, we have demon-
strated that these cells respond to Ang II to increase
[3H]thymidine incorporation in a time- and dose-depen-
dent manner with a maximal response achieved at 1 mM
(Fig. 3A). The Ang II-induced DNA synthesis in cultured
RMICs does not require the presence of insulin, but other
Fig. 2. Electron microscopic localization of
angiotensin II receptor (AT1) (A), endothelin
(ET)B (B), and bradykinin (B)2 receptors (C) in
rat RMICs. Abbreviations are: DT, distal
tubule; IC; RMIC, renomedullary interstitial
cells; CD, collecting duct; CP, cell process; EC,
peritubular capillary endothelial cells. Stain:
Uranyl acetate, lead citrate. Magnification is
(A) 37200; (B) 312000; (C)39600.
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growth factors may play a synergistic role because treat-
ment of RMICs with insulin-depleted serum produces
greater increase in DNA synthesis [13]. In addition, Ang II
potently stimulates extracellular matrix (ECM) synthesis as
detected by trans-35S incorporation. Although the signal
transduction pathways of Ang II actions on RMICs are
not fully understood, our studies suggest that increases in
intracellular inositol 1,4,5-triphosphate (IP3) followed by
intracellular Ca21 ([Ca21]i) mobilization may be in-
volved [12]. Indeed, Ang II induces marked increases in
IP3 and [Ca
21]i but does not appear to alter either basal or
forskolin-induced intracellular cAMP [13]. All of these
cellular responses to Ang II in cultured RMICs are com-
pletely inhibited by the AT1 receptor antagonist, losartan,
but not by the AT2 receptor antagonist PD 123319 [13].
Thus, our studies indicate that the type 1 RMICs are the
primary sites for AT1A receptors in the inner stripe of the
outer medulla, and this subtype of AT1 receptors may
mediate Ang II stimulation of intracellular IP3 and [Ca
21]i
and cell proliferation in RMICs. In contrast, AT2 receptor
binding or mRNA is not detected in RMICs isolated and
cultured from the adult rat kidney, but they occur in
embryonic RMICs [14]. In embryonic RMICs, we have
observed recently that Ang II inhibits basic fibroblast
growth factor-induced DNA synthesis and that this effect is
mediated by AT2 receptors [14]. These results suggest that,
as in coronary endothelial cells [15], Ang II may exert a
dual role in the regulation of cell proliferation with a
stimulation of the cell growth by AT1 receptors and an
antiproliferative effect mediated by AT2 receptors.
CELLULAR LOCALIZATION AND ACTIONS OF ET
RECEPTOR SUBTYPES IN RMICS
ETs, a family of three isopeptides (ET-1, ET-2, and
ET-3), initially isolated from cultured porcine aortic endo-
thelial cells [16], are well recognized as potent paracrine
and autocrine factors in the kidney [17, 19]. Several renal
cell types, including vascular endothelial cells, cultured
mesangial cells, and tubular epithelial cells, express mRNA
for ET-1 and its receptor subtypes, ETA and ETB [17, 18].
In the kidney, ET-1 is a potent vasoconstrictor and de-
creases glomerular filtration rate and renal plasma flow and
sodium and water excretion [17, 18]. However, at low doses,
ET-1 may vasodilate in the kidney, leading to diuresis and
natriuresis probably mediated by interaction with nitric
oxide (NO) [17, 18].
Two subclasses of ET-1 receptors are thought to mediate
the physiological responses to ET-1, and the receptors and
their mRNAs have been identified and characterized in
different structures of the renal medulla by radioreceptor
assays, in vitro autoradiography, or RT-PCR [19, 20]. A
high density of ET-1 receptor binding occurs primarily in
the inner medulla and glomeruli, with moderate-to-low
levels in the inner stripe of the outer medulla and the
interglomerular region of the cortex, which corresponds to
the proximal convoluted tubules [20]. However, ET recep-
tor binding has not yet been localized at the cellular level in
the kidney. Using electron microscopic autoradiography,
Fig. 3. Effects of angiotensin II (Ang II), endothelin (ET), and bradyki-
nin (BK) on [3H]thymidine incorporation in cultured rat renomedullary
interstitial cells (RMICs). Top: Ang II (1 mM) potently stimulates
[3H]thymidine incorporation at 8 hours, and this effect is fully blocked by
the AT1 antagonist, losartan (1 mM), but not by the AT2 antagonist, PD
123319 (1 mM). Middle: ET-1 (1 mM) markedly increases [3H]thymidine
incorporation at 24 hours when nitric oxide production is blocked by 1 mM
NNA. The ETA receptor antagonist, BQ123 (1 mM), fully blocks this
response, whereas the ETB receptor agonist, sarafotoxin 6c (1 mM), has no
effect. Bottom: BK (100 pM) stimulates [3H]thymidine incorporation at 24
hours, which is abolished by the B2 receptor selective antagonist, HOE140
(1 mM), but the B1 receptor antagonist, Des-Arg
9[Leu8]BK (1 mM), has no
significant effect. **P , 0.001 versus control.
Zhuo et al: Vasoactive peptide receptors in renomedullary interstitial cells S-25
we thus localized ET-1 receptors in the rat kidney following
in vivo labeling with 125I-ET-1, analogous to the technique
used for localization of AT1 receptors [12]. Specific ET-1
receptor binding is almost exclusively localized to the
fenestrated endothelial cells of glomerular capillaries and
peritubular capillaries in both cortex and medulla, and
there is no appreciable binding in cells of glomerular
mesangium, renal tubules, and the interstitium [21]. Be-
cause ET-1 receptor binding has been shown in cultured
mesangial cells and RMICs and microdissected renal tu-
bules by binding assays in vitro [17, 18, 22], we reasoned
that the lack of ET-1 receptor binding in these cells in vivo
could be due to the physical barrier that prevents penetra-
tion of the circulating radioligand into these structures.
ET-1 receptor subtypes were thus mapped in fresh thin
sections of kidney to investigate whether other renal com-
ponents also possess ET-1 receptor binding [20]. Tissues
were incubated with the radioligand in the presence or
absence of ET-1 receptor subtype-selective ligands to de-
termine ET-1 receptor subtypes. High densities of ETB
receptors were found in the glomerulus, proximal tubule,
and the outer and inner medulla, whereas ETA receptor
binding is much lower throughout the kidney (Fig. 1B) [20].
At the electron microscopic level, as for in vivo labeling,
ET-1 receptor binding is localized primarily to the fenes-
trated endothelium of glomerular capillaries and peritubu-
lar capillaries of the cortex, inner stripe of the outer
medulla, and the inner medulla. However, ET-1 receptor
binding also occurs in RMICs of the inner medulla and to
a lesser extent in the inner stripe (Fig. 2B). The ETB
receptor-selective agonist, sarafotoxin 6c (S6c), almost
completely abolishes ET-1 receptor binding in the vascular
endothelium throughout the kidney, whereas the ETA
receptor selective antagonist, BQ123, is without effect [20].
Interestingly, both BQ123 and S6c partially inhibit the
binding in RMICs in the medulla. These results indicate
that in the endothelium of the glomerular and peritubular
capillaries, ET-1 binds to ETB receptors, whereas both ETA
and ETB are present in RMICs [20].
Cultured RMICs contain high-affinity binding sites that
are selective for ET-1 and ET-2 [22]. In these cells, ET-1
stimulates phosphatidylinositol hydrolysis, which results in
increases in intracellular IP3 and [Ca
21]i, and activates
phospholipase A2 to increase PG E2 production [22]. In
addition, ET-1 contracts RMICs accompanied by increased
F-actin microfilament staining, which may play a role in
modifying renal medullary function including the microcir-
culation and urinary concentration [23]. However, it re-
mains unclear which ET receptor subtype is involved in
these cellular responses, because subtype-selective antago-
nists were not used in these studies [22, 23]. Recently, we
have examined the effects of ET on cell proliferation and
ECM synthesis in cultured RMICs and determined the
receptor subtypes involved [24]. Although [3H]thymidine
incorporation and ECM synthesis are not altered by ET-1
alone, they both increase in response to ET-1 when NO
synthesis is blocked [24]. These cellular responses are
completely inhibited by the ETA receptor antagonist,
BQ123 (1 mM), but not the ETB receptor agonist S6c (1
mM), consistent with the presence of ETA receptors and
mRNA in these cells (Fig. 3B). In contrast, the role of ETB
receptor binding, as detected by electron microscopic au-
toradiography, is currently unknown, although renal vascu-
lar effects including vasoconstriction and dilatation and
tubular actions have been described for ETB receptors [18].
More studies are thus needed to characterize further the
paracrine and autocrine roles of ET and its receptor
subtypes in the regulation of renal physiological processes
and in pathogenesis of renal disease.
CELLULAR LOCALIZATION AND ACTIONS OF
BRADYKININ B2 RECEPTORS IN RMICS
The major effector of the renal kallikrein-kinin system,
BK, is an important intrarenal paracrine and/or autocrine
factor implicated in the regulation of renal hemodynamics
and tubular electrolyte fluxes and water transport [2, 25]. In
the kidney, BK is a potent vasodilator, reducing renal
vascular resistance, increasing renal blood flow, and caus-
ing diuresis, natriuresis, and lower urine osmolarity [2, 25].
BK also produces many renal responses indirectly by
interacting with local PGs or the renin-angiotensin system
[2, 25]. BK receptors in the kidney have been studied
previously at the light microscopic level, where they are
found in the inner stripe of the outer medulla, inner medulla,
and the pelvic capsule [26, 27]. The cellular localization of
the B2 receptors is, however, not known. To help elucidate
the mechanisms of renal actions of BK, we localized B2
binding sites in the rat kidney using in vitro autoradiogra-
phy and high-resolution electron microscopic autoradiog-
raphy following i.v. administration of a radiolabeled ligand,
125I-HPP-HOE 140, a derivative of the highly selective B2
receptor antagonist, HOE 140 (3 to 4-hydroxyphenol-
propionyl-DArg0-[Hyp3-Thi5-D-Tic7-Oic8]-BK) [26, 28]. B2
receptor binding is present throughout the entire renal
medulla, with the highest density in the inner medulla and
in longitudinal bands traversing the inner stripe of the
outer medulla. Little binding is observed in the cortex (Fig.
1C). At the electron microscopic level, B2 binding is widely
distributed, including distal tubules, thin limbs of the loop
of Henle, collecting ducts, and peritubular capillary endo-
thelium (Fig. 2C). Interestingly, B2 receptor binding also
occurs in RMICs throughout the inner stripe of the outer
medulla and the inner medulla (Fig. 2C) [28]. In HPLC
studies in rats pretreated with the ACE inhibitor, perindo-
pril, to reduce degradation of the radioligand in vivo, B2
receptor binding persisted at the sites described earlier
here, but cortical binding was abolished. This indicates that
the cortical binding following in vivo labeling is due to
tubular uptake of the degraded radioligand, whereas au-
thentic B2 receptors occur predominantly in the renal
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tubules, vascular endothelium, and RMICs in the medulla
[28]. Binding assays [28, 29] and RT-PCR analysis [28]
show that cultured RMICs also express B2 receptor binding
sites and mRNA. In cultured RMICs, BK significantly
increases cAMP and cGMP levels, but the latter response is
dependent on the production of NO. [3H]thymidine incor-
poration and ECM synthesis are also stimulated by BK, and
these responses are abolished by the B2 receptor antago-
nist, HOE 140, whereas the B1 receptor antagonist,
desArg9[Leu8]BK (1 mM) is without effect (Fig. 3C) [28].
The presence and expression of B2 receptors in RMICs in
culture and in vivo support an important role for BK in the
regulation of renal medullary hemodynamics and urinary
excretion of sodium and water through the B2 receptor.
COLOCALIZATION OF AT1, ETA AND ETB, AND B2
RECEPTORS IN RMICS
Various vasoactive peptides appear to interact physiolog-
ically at multiple intrarenal sites to influence renal hemo-
dynamics and tubular function [1–3]. In the cortex, Ang II
and ET act as vasoconstrictors to decrease renal blood flow
and glomerular filtration rate, whereas BK causes vasodi-
latation and increases glomerular capillary permeability [2].
In the medulla, Ang II and ET cause vasoconstriction of
outer medullary descending vasa recta and thereby de-
crease vasa recta and papillary blood flow, whereas BK
exerts opposite effects [2]. These results suggest a func-
tional interplay between these vasoactive peptides at mul-
tiple cellular sites of the kidney. In accordance with these
functional interactions, receptor-mapping studies have re-
vealed that the distributions of AT1, ETA and ETB, and B2
receptors closely overlap at several anatomical sites, includ-
ing the renal vasculature, glomeruli, and the inner stripe of
the outer medulla [4, 8, 19, 20, 27, 28]. In the cortex, the
distributions of AT1 and ETB receptors are similar in the
glomeruli and superficial proximal tubules [4, 16, 18–20]. In
contrast, B2 receptor density is low in the cortex [27]. AT1
receptors are predominantly in mesangial cells [6, 8],
whereas ETB receptors are present mainly in endothelial
cells of glomerular capillaries [20, 21]. In the medulla, ETB
and B2 receptors are very abundant in the inner medulla
toward the tip of the papilla [20, 28], whereas AT1 recep-
tors are not readily detected in this region (Fig. 1) [4, 8].
However, receptor binding sites for these vasoactive pep-
tides all occur in the inner stripe of the outer medulla,
where these receptors have been identified in rat type I
RMICs or cultured rat RMICs (Fig. 2) [4, 11–13, 19, 21, 28,
29]. The concurrent distribution of multiple peptide recep-
tors in RMICs provides a cellular basis for these vasoactive
peptides to act alone, or to interact, in the regulation of
renal medullary hemodynamics, tubular transport pro-
cesses, and probably long-term blood pressure homeostasis.
Moreover, the effects of Ang II, ET, and BK on cell
proliferation and ECM synthesis in RMICs (Fig. 3) may
also imply important roles for these peptides in patholog-
ical processes of chronic progressive renal diseases.
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